These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 30108375)
41. Can Confirmatory Biopsy be Omitted in Patients with Prostate Cancer Favorable Diagnostic Features on Active Surveillance? Satasivam P; Poon BY; Ehdaie B; Vickers AJ; Eastham JA J Urol; 2016 Jan; 195(1):74-9. PubMed ID: 26192258 [TBL] [Abstract][Full Text] [Related]
42. Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy. Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Pennisi M; Morgia G Scand J Urol; 2017 Aug; 51(4):260-263. PubMed ID: 28513296 [TBL] [Abstract][Full Text] [Related]
43. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340 [TBL] [Abstract][Full Text] [Related]
44. Prostate cancer screening in Tyrol, Austria: experience and results. Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519 [TBL] [Abstract][Full Text] [Related]
45. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml. Bermúdez-Tamayo C; Martín Martín JJ; González Mdel P; Pérez Romero C Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853 [TBL] [Abstract][Full Text] [Related]
46. Diagnostic prostate biopsy performed in a non-academic center increases the risk of re-classification at confirmatory biopsy for men considering active surveillance for prostate cancer. Wong LM; Ferrara S; Alibhai SM; Evans A; Van der Kwast T; Trottier G; Timilshina N; Toi A; Kulkarni G; Hamilton R; Zlotta A; Fleshner N; Finelli A Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):69-74. PubMed ID: 25487136 [TBL] [Abstract][Full Text] [Related]
47. Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance? Chen DJ; Falzarano SM; McKenney JK; Przybycin CG; Reynolds JP; Roma A; Jones JS; Stephenson A; Klein E; Magi-Galluzzi C BJU Int; 2015 Aug; 116(2):220-9. PubMed ID: 25060664 [TBL] [Abstract][Full Text] [Related]
48. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer. Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695 [TBL] [Abstract][Full Text] [Related]
49. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression. Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593 [TBL] [Abstract][Full Text] [Related]
50. Preliminary results of the Spanish Association of Urology National Registry in Active Surveillance for prostate cancer. Rubio-Briones J; Borque A; Esteban LM; Iborra I; López PA; Gil JM; Pallás Y; Fumadó L; Martínez-Breijo S; Chantada V; Gómez E; Quicios C; Congregado CB; Medina R; Ortiz M; Montesino M; Clar F; Soto J; Campá JM Actas Urol Esp; 2016; 40(1):3-10. PubMed ID: 26115777 [TBL] [Abstract][Full Text] [Related]
51. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies. Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632 [TBL] [Abstract][Full Text] [Related]
52. Should follow-up biopsies for men on active surveillance for prostate cancer be restricted to limited templates? Wong LM; Trottier G; Toi A; Lawrentschuk N; Van der Kwast TH; Zlotta A; Kulkarni G; Hamilton R; Trachtenberg J; Evans A; Timilshina N; Fleshner NE; Finelli A Urology; 2013 Aug; 82(2):405-9. PubMed ID: 23735610 [TBL] [Abstract][Full Text] [Related]
53. The number of cores at first biopsy may suggest the need for a confirmatory biopsy in patients eligible for active surveillance-implication for clinical decision making in the real-life setting. Villa L; Salonia A; Capitanio U; Scattoni V; Abdollah F; Suardi N; Dell'Oglio P; Freschi M; Montorsi F; Briganti A Urology; 2014 Sep; 84(3):634-41. PubMed ID: 25059594 [TBL] [Abstract][Full Text] [Related]
54. A solitary positive prostate cancer biopsy does not predict a unilateral lesion in radical prostatectomy specimens. Koie T; Mitsuzuka K; Narita S; Yoneyama T; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C Scand J Urol; 2015 Apr; 49(2):103-7. PubMed ID: 25165894 [TBL] [Abstract][Full Text] [Related]
55. Reflex PCA3 messenger ribonucleic acid testing: validation of postbiopsy urine samples and correlation with prostate biopsy findings in ∼2000 patients. Brown JG; Fulmer JR; Romano J; Pownell J; Rigler W; Wirtshafter A; Sarno M; Shappell SB Urology; 2014 Nov; 84(5):1172-80. PubMed ID: 25443926 [TBL] [Abstract][Full Text] [Related]
56. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy. Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236 [TBL] [Abstract][Full Text] [Related]
57. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. Newcomb LF; Thompson IM; Boyer HD; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Ellis WJ; Fazli L; Feng Z; Gleave ME; Kunju P; Lance RS; McKenney JK; Meng MV; Nicolas MM; Sanda MG; Simko J; So A; Tretiakova MS; Troyer DA; True LD; Vakar-Lopez F; Virgin J; Wagner AA; Wei JT; Zheng Y; Nelson PS; Lin DW; J Urol; 2016 Feb; 195(2):313-20. PubMed ID: 26327354 [TBL] [Abstract][Full Text] [Related]
58. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645 [TBL] [Abstract][Full Text] [Related]
59. Magnetic resonance imaging on disease reclassification among active surveillance candidates with low-risk prostate cancer: a diagnostic meta-analysis. Guo R; Cai L; Fan Y; Jin J; Zhou L; Zhang K Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):221-8. PubMed ID: 25986915 [TBL] [Abstract][Full Text] [Related]
60. Performance of biopsy factors in predicting unfavorable disease in patients eligible for active surveillance according to the PRIAS criteria. Russo GI; Castelli T; Favilla V; Reale G; Urzì D; Privitera S; Fragalà E; Cimino S; Morgia G Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):338-42. PubMed ID: 26032650 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]